Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17459599 | 0.82 | — | — | |
| SCHEMBL9458428 | 0.76 | — | — | |
| SCHEMBL8480417 | 0.76 | — | — | |
| SCHEMBL13398656 | 0.75 | — | — | |
| SCHEMBL1786653 | 0.73 | — | — | |
| SCHEMBL1188054 | 0.72 | KMT2A (0.37) | POLB | |
| SCHEMBL3347901 | 0.71 | — | — | |
| SCHEMBL10160748 | 0.71 | — | — | |
| SCHEMBL9368244 | 0.71 | POLB (0.31) | POLB | |
| SCHEMBL17282285 | 0.71 | KMT2A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4252848-A2 | OXYSTEROLS AND METHODS OF USE THEREOF | Sage Therapeutics, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3529257-B1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2023-05-10 | — | — | EP | disclosed |
| WO-2022070288-A1 | NITROGEN-CONTAINING BICYCLIC COMPOUND | 旭化成ファーマ株式会社 | 2022-04-07 | — | — | WO | disclosed |
| US-20210380631-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2021-12-09 | — | — | US | disclosed |
| US-11149054-B2 | Oxysterols and methods of use thereof | SAGE THERAPEUTICS, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20190248829-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2019-08-15 | — | — | US | disclosed |
| WO-2018075699-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| US-20160244670-A1 | LIQUID CRYSTAL COMPOUND HAVING VINYLENE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160244670-A1 | LIQUID CRYSTAL COMPOUND HAVING VINYLENE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-08-25 | — | — | US | disclosed |
| EP-2344483-B1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2013-05-01 | — | — | EP | disclosed |
| WO-2008094574-A2 | FURANONE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008094574-A2 | FURANONE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| US-5238602-A | Electrooptical cells | HOFFMANN LA ROCHE INC. (US) | 1993-08-24 | — | — | US | disclosed |
| US-5013478-A | Electromagnetic radiation resistance; miscibility; dielectrics; rotation and guest/host cells | HOFFMANN-LA ROCHE INC. (US) | 1991-05-07 | — | — | US | disclosed |
| US-4980486-A | Phenyl isothiocyanates | HOFFMANN-LA ROCHE INC. (US) | 1990-12-25 | — | — | US | disclosed |
| US-4915480-A | Liquid crystalline compounds and mixtures | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-04-10 | — | — | US | disclosed |
| US-4709030-A | 4-ALKENYL OR 2Z-ALKENYL POLYPHENYL COMPOUNDS; ELECTRO-OPTICS | HOFFMANN-LA ROCHE INC. (US) | 1987-11-24 | — | — | US | disclosed |
| US-4676604-A | RADIATION RESISTANCE; MISCIBILITY; ROTATION ELECTROPTICAL CELLS | HOFFMANN-LA ROCHE INC. (US) | 1987-06-30 | — | — | US | disclosed |
| US-4621901-A | ELECTROOPTICS | HOFFMANN-LA ROCHE INC. (US) | 1986-11-11 | — | — | US | disclosed |
| US-4565425-A | Liquid crystals | HOFFMANN-LA ROCHE INC. (US) | 1986-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380631-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | NR1H3, NR1H2, HSD17B7 | POLB 4227/4885 |
| US-20190248829-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | NR1H3, NR1H2, HSD17B7 | POLB 4156/4885 |
| US-11149054-B2 | Oxysterols and methods of use thereof | NR1H3, NR1H2, HSD17B7 | POLB 4156/4885 |
| US-20160244670-A1 | LIQUID CRYSTAL COMPOUND HAVING VINYLENE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | OCIAD1, OCIAD2, PIEZO1 | POLB 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.